Table 1.
Characteristics of patients with IgA monoclonal gammopathy of undetermined significance (MGUS) or IgA myeloma.
| MGUS | Myeloma | |
| Patients, n | 6 | 29 |
| Patients with available biological data, n | 6 | 20 |
| Male sex, n (%) | 2 (33.3%) | 9 (45.0%) |
| Age (year) | ||
| Median | 76.6 | 75.1 |
| Range | 66–97 | 57–95 |
| Monoclonal IgA (g/L) | ||
| Median | 8.0 | 17.0 |
| Range | 3.0–19.0 | 4.0–57.0 |
| Bone marrow plasma cells (%) | n =2 | n = 19 |
| Median | 8 | 52 |
| Range | 1–16 | 1–89 |
| β2-microglobulin (mg/L) | ||
| Median | NA | 4.2 |
| Range | NA | 1.1–14.0 |
| Leukocytes (×109/L) | ||
| Median | 7.1 | 4.6 |
| Range | 4.1–11.8 | 1.3–9.0 |
| Hemoglobin (g/dl) | ||
| Median | 11.2 | 9.7 |
| Range | 7.6–126 | 5.4–15.3 |
| Platelets (×109/L) | ||
| Median | 218.5 | 164.0 |
| Range | 132–356 | 24–269 |
| ISS (n = 8)* | ||
| Stage I, n (%) | - | 2 (25.0%) |
| Stage II, n (%) | - | 2 (25.0%) |
| Stage III, n (%) | - | 4 (50.0%) |
| DSS (n = 22) | ||
| Stage I, n (%) | - | 0 (0%) |
| Stage II, n (%) | - | 9 (40.9%) |
| Stage III, n (%) | - | 13 (59.1%) |
n, number; NA, not available; ISS, International System Staging; DSS, Durie–Salmon Staging.
*
The β2-microglobulin level was available for only eight myeloma patients.